Trasylol, an anti-bleeding medication, is at risk of being pulled from the market after a study found that patients using the drug are at higher risk of dying than those using alternative medicines.
Bayer AG manufacturers the drug and is still debating whether to recall the medication.
Study Compares Drugs
A recent study compared Trasylol with two other medications that surgeons also administer to prevent blood loss during heart surgery.
Bayer is reportedly facing several lawsuits that claim the medication led to excess deaths and other health complications in patients.
Background on Trasylol
Trasylol was approved in 1993 and problems began to arise in patients in 2006, following a study that linked the drug to risks such as heart attack, stroke and kidney failure.
This latest study analyzed 2,300 patients and found that those given Trasylol as opposed to other medications during heart surgery had a higher death rate.
“I think the results are quite definitive, certainly for high-risk cardiac surgery, and it’s going to be very tough to justify its use in lower-risk surgery,” explains Dean A. Fergusson, who headed the study.
More than 80 lawsuits have reportedly been filed against Bayer involving patients who have been harmed by Trasylol.
(Source: Associated Press)
Have you been endured health problems due to the use of Trasylol? If so, please contact us today to speak with an experienced attorney about the resources available to you.
